BUZZ-Aeterna Zentaris Inc: Will complete late-stage study by year end
** Canadian drug developer's U.S.-listed shares up 27 pct at $3.39; Toronto-listed shares also gain 27 pct to C$4.88
** Says will complete by year-end a confirmatory late-stage trial of its drug for evaluating growth hormone deficiency
** Says it believes the study meets FDA and European regulators' design expectations for approval
* Expects to submit application for U.S. approval by mid-year 2017, if the study is successful
** Up to Friday's close, the U.S.-listed stock had fallen about 95 pct in the past 12 months
© Thomson Reuters 2016 All rights reserved.